Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.26M | -64.21M | -63.53M | -67.66M | -40.91M |
| Total Depreciation and Amortization | 739.00K | 723.00K | 699.00K | 664.00K | 627.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.68M | 47.33M | 48.03M | 53.82M | 27.07M |
| Change in Net Operating Assets | -3.97M | -5.96M | -4.11M | -7.21M | -9.35M |
| Cash from Operations | -23.82M | -22.11M | -18.92M | -20.39M | -22.56M |
| Capital Expenditure | -574.00K | -480.00K | -522.00K | -488.00K | -588.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.14M | -17.21M | -12.94M | 5.00M | 9.00M |
| Cash from Investing | -13.71M | -17.69M | -13.46M | 4.51M | 8.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -54.00K | -59.00K | -59.00K | -58.00K | -55.00K |
| Issuance of Common Stock | 32.57M | 28.09M | 27.77M | 29.30M | 27.23M |
| Repurchase of Common Stock | -41.00K | -106.00K | -81.00K | -80.00K | -80.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -232.00K | -460.00K | -684.00K | -855.00K | -623.00K |
| Cash from Financing | 32.24M | 27.47M | 26.95M | 28.31M | 26.47M |
| Foreign Exchange rate Adjustments | 430.00K | 464.00K | 396.00K | 241.00K | 283.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.86M | -11.87M | -5.03M | 12.67M | 12.61M |